GlassScriptPhysician profile
Taylor Barnett
NPI 1487091005
$901.63
in general payments reported to CMS, 2019-2025
13 companies · $17.10 in 2025
The $17.10 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2022: $101 · 2023: $59.88 · 2024: $153 · 2025: $17.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $229.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $253.94 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $131.42 | 2019-2025 | Opdivo |
| Seagen INC. | $102.70 | 2019 | |
| Astellas Pharma US INC | $99.99 | 2019 | |
| Lilly USA, LLC | $85.34 | 2022 | |
| Janssen Biotech, INC. | $54.94 | 2024 | Carvykti |
| Merck Sharp & Dohme LLC | $43.71 | 2024 | Keytruda |
| Amgen INC. | $33.13 | 2023 | Prolia |
| Pfizer INC. | $28.79 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $20.90 | 2024 | |
| Incyte Corporation | $20.02 | 2024 | Jakafi, Monjuvi, Pemazyre |
| Gilead Sciences, INC. | $13.89 | 2023 | |
| Stemline Therapeutics INC. | $12.86 | 2023 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Barnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.